Journal
PEPTIDES
Volume 59, Issue -, Pages 34-41Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2014.07.002
Keywords
Renin-angiotensin system - RAS; Lipid metabolism; Glucose metabolism; ACEi; ARBs
Funding
- CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil)
- CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil)
- FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil) [PRONEX APQ04758-10]
- INCT NanoBiofar (CNPq/FAPEMIG)
Ask authors/readers for more resources
Angiotensin-(1-7) is one of the most important active peptides of the renin-angiotensin system (RAS) with recognized cardiovascular relevance; however several studies have shown the potential therapeutic role of Ang-(1-7) on treating and preventing metabolic disorders as well. This peptide achieves a special importance considering that in the last few decades obesity and metabolic syndrome (MS) have become a growing worldwide health problem. Angiotensin (Ang) II is the most studied component of RAS and is increased during obesity, diabetes and dyslipidemia (MS); some experimental evidence has shown that Ang II modulates appetite and metabolism as well as mechanisms that induce adipose tissue growth and metabolism in peripheral organs. Recent articles demonstrated that Ang-(1-7)/Mas axis modulates lipid and glucose metabolism and counterregulates the effects of Ang II. Based on these data, angiotensin-converting enzyme 2 (ACE2)/Ang-(1-7)/Mas pathway activation have been advocated as a new tool for treating metabolic diseases. This review summarizes the new evidence from animal and human experiments indicating the use of Ang-(1-7) in prevention and treatment of obesity and metabolic disorders. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available